Nuritas combines artificial intelligence and genomics to discover and unlock natural Bioactive Peptides with extraordinary health benefits with the potential to change the lives of billions.
Nuritas was founded in 2014 by mathematician and computational biologist, Dr Nora Khaldi, to deliver incremental gains to discovery and to create a disruptive opportunity for real change.
Nuritas combines the power of artificial intelligence (AI) with deep learning and ‘omics’ analyses to discover novel peptides with therapeutic and commercial applications. By integrating our AI predictive platform with in-house laboratories, we can rapidly discover and preclinically validate peptide therapeutics within months rather than years.
Nuritas's discovery approach combines predictions generated by machine learning with in vitro laboratory testing. This iterative feedback loop equips the machine with the knowledge to discern what makes a peptide prediction effective in vivo. In this way, we have created an unparalleled technology that for any disease can capture the core information that maximizes peptide activity, binding, stability, and bioavailability.
Our patented discoveries have applications in many sectors including pharmaceuticals, health and wellness, dermatology, animal and plant health.